Market OverviewThe Global Osteoarthritis Pain Drugs Market is valued at USD 10.32 Billion in 2023 and is projected to reach a value of USD 17.96 Billion by 2032 at a CAGR (Compound Annual Growth Rate) ...

The LATAM pain management drugs market was valued at $2,683.82 million in 2019, and is projected to reach $3,383.20 million by 2027, registering a CAGR of 3.5% from 2020 to 2027. The length of pain ...

Pfizer (PFE) is ending a late-stage trial of its once-daily GLP-1 pill, Danuglipron, after a participant experienced a liver ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Pfizer (PFE – Research Report), with a price target of ...

As healthcare delivery becomes increasingly digital, forward-looking organizations are investing in technology not just to ...

In a report released today, Trung Huynh from UBS maintained a Hold rating on Pfizer (PFE – Research Report), with a price target of $24.00. The ...

Find insight on Pfizer, Roche and more in the latest Market Talks covering the Health Care sector.

Pfizer shares moved lower in premarket trading Monday after the drugmaker said it is scrapping its experimental weight-loss pill danuglipron, keeping the company on the sidelines of the booming ...

Nvidia's healthcare strategy leverages AI to revolutionize medical imaging and diagnostics, according to healthcare GM Kimberly Powell.

What Happened? A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous ...

Five years ago, volunteers rolled up their sleeves in the first clinical trial of a vaccine against COVID-19, as the new ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...